Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shugan Jieyu Capsule versus fluoxetine for mild to moderate depression
ChiCTR1900026443Phase 4Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Nov 2019
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Shugan Jieyu and fluoxetine in major depressive disorder (MDD) (3 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoints: MRI, Hamilton Depression Rating Scale and 2 more. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
Shugan Jieyufluoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR1900026443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026443.